Madrigal Pharmaceuticals Inc stock is traded at $399.63, with a volume of 1,086,327. It is down -0.12% in the last 24 hours and down -19.50% over the past month. Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.
Previous Close:
$400.10
Open:
$400.00
24h Volume:
1,086,327
Relative Volume:
1.35
Market Cap:
$9.28B
Revenue:
$1.13B
Net Income/Loss:
-$309.44M
P/E Ratio:
-
EPS:
-$12.80
Net Cash Flow:
-$275.41M
1W Performance:
-7.14%
1M Performance:
-19.50%
6M Performance:
-25.96%
1Y Performance:
-18.21%
1-Day Range:
$378.28$401.61
1-Week Range:
$353.54$482.73
52-Week Range:
$353.54$615.00
Madrigal Pharmaceuticals Inc Stock (MDGL) Company Profile
Name
Madrigal Pharmaceuticals IncSector
HealthcareIndustry
BiotechnologyPhone
404-380-9263Address
200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS